2025 H2 -tulosraportti
34 päivää sitten
‧38 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 782 | - | - | ||
| 15 000 | - | - | ||
| 2 217 | - | - | ||
| 2 070 | - | - | ||
| 513 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·5 t sittenThe boat is fully loaded. Now we depart. First departurev10 kr. Disembarkation port side. Happy Easter everyone!
·5 t sittenBetting we meet the Boat Boss out there on the open sea⛵Or the ship sank...who knows..Loaded and ready, ship ahoy⚓
9 t sitten · Muokattu9 t sitten · Muokattuhttps://www.linkedin.com/posts/c-ray-therpeutics_xdc-2026-recap-activity-7445077543470403584-SM1L?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY 🎤 Several days ago, we took a step — bringing together leading voices from across the global RDC ecosystem at XDC 2026. Isotope producers, ligand innovators, clinical-stage developers. Not just to share a stage, but to see Chengdu. Because Chengdu is not just a conference venue. It has become one of China's most significant radiopharmaceutical hubs — in infrastructure, in policy support, in the speed at which things get built. Visiting the Chengdu Medical City, our guests saw that firsthand. And what they saw in C-Ray was something specific: a single site where the full chain lives — from process development and radiolabeling to cGMP manufacturing and cold-chain logistics. One site. One stop. The conversations on stage reflected exactly why that matters. Ligand platforms are diversifying. Novel isotopes are moving from supply bottleneck to clinical reality. New therapeutic modalities are expanding what radiopharmaceuticals can treat and how. These are not separate trends — they are converging. And they all require the same thing: a manufacturing and development partner who can move with them. That is the role C-Ray was built to play. We are a radiopharmaceutical CRDMO headquartered in Chengdu — at the intersection of China's growing capabilities and the global pipeline that needs them. This is just the beginning. To every speaker, partner, and delegate who made the journey: thank you! 🌹 NorthStar Medical Radioisotopes, LLCThor Medical ASA, Navigo, Oncoinvent ASA And to those who haven't yet — we hope to welcome you to Chengdu, to this industry's next chapter, and to C-Ray. 👐 #XDC2026 #Radiopharmaceuticals #CRDMO #RDC #Chengdu #AlphaTherapy #NuclearMedicine #ligand #isotope #Ac225 #Pb212 #Lu177
·10 t sittenThere should be a minimum requirement for volume on the opening/closing auctions. I think it's a joke.
·4 t sittenIt would have been better if there was a rule that everyone HAD to show their portfolio for stocks they comment on so that people can decide how seriously they want to take the comment from that particular person. Ideally, everyone has skin in the game. Why is one here pumping up the stock while one themselves only has 4% invested in the stock? If it is as good as one says, then why not have 20, 30 or 40% of their portfolio in TRMED? Perhaps the number of shares and average cost basis would also have been interesting? Someone who has an average cost basis of 0.8kr is perhaps euphoric and should perhaps not give advice to others who have an average cost basis of 3 or 4kr for example?
·10 t sittenThe shorts are bleeding now :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
34 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sittenThe boat is fully loaded. Now we depart. First departurev10 kr. Disembarkation port side. Happy Easter everyone!·5 t sittenBetting we meet the Boat Boss out there on the open sea⛵Or the ship sank...who knows..Loaded and ready, ship ahoy⚓
- 9 t sitten · Muokattu9 t sitten · Muokattuhttps://www.linkedin.com/posts/c-ray-therpeutics_xdc-2026-recap-activity-7445077543470403584-SM1L?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY 🎤 Several days ago, we took a step — bringing together leading voices from across the global RDC ecosystem at XDC 2026. Isotope producers, ligand innovators, clinical-stage developers. Not just to share a stage, but to see Chengdu. Because Chengdu is not just a conference venue. It has become one of China's most significant radiopharmaceutical hubs — in infrastructure, in policy support, in the speed at which things get built. Visiting the Chengdu Medical City, our guests saw that firsthand. And what they saw in C-Ray was something specific: a single site where the full chain lives — from process development and radiolabeling to cGMP manufacturing and cold-chain logistics. One site. One stop. The conversations on stage reflected exactly why that matters. Ligand platforms are diversifying. Novel isotopes are moving from supply bottleneck to clinical reality. New therapeutic modalities are expanding what radiopharmaceuticals can treat and how. These are not separate trends — they are converging. And they all require the same thing: a manufacturing and development partner who can move with them. That is the role C-Ray was built to play. We are a radiopharmaceutical CRDMO headquartered in Chengdu — at the intersection of China's growing capabilities and the global pipeline that needs them. This is just the beginning. To every speaker, partner, and delegate who made the journey: thank you! 🌹 NorthStar Medical Radioisotopes, LLCThor Medical ASA, Navigo, Oncoinvent ASA And to those who haven't yet — we hope to welcome you to Chengdu, to this industry's next chapter, and to C-Ray. 👐 #XDC2026 #Radiopharmaceuticals #CRDMO #RDC #Chengdu #AlphaTherapy #NuclearMedicine #ligand #isotope #Ac225 #Pb212 #Lu177
- ·10 t sittenThere should be a minimum requirement for volume on the opening/closing auctions. I think it's a joke.·4 t sittenIt would have been better if there was a rule that everyone HAD to show their portfolio for stocks they comment on so that people can decide how seriously they want to take the comment from that particular person. Ideally, everyone has skin in the game. Why is one here pumping up the stock while one themselves only has 4% invested in the stock? If it is as good as one says, then why not have 20, 30 or 40% of their portfolio in TRMED? Perhaps the number of shares and average cost basis would also have been interesting? Someone who has an average cost basis of 0.8kr is perhaps euphoric and should perhaps not give advice to others who have an average cost basis of 3 or 4kr for example?
- ·10 t sittenThe shorts are bleeding now :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 782 | - | - | ||
| 15 000 | - | - | ||
| 2 217 | - | - | ||
| 2 070 | - | - | ||
| 513 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
2025 H2 -tulosraportti
34 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sittenThe boat is fully loaded. Now we depart. First departurev10 kr. Disembarkation port side. Happy Easter everyone!·5 t sittenBetting we meet the Boat Boss out there on the open sea⛵Or the ship sank...who knows..Loaded and ready, ship ahoy⚓
- 9 t sitten · Muokattu9 t sitten · Muokattuhttps://www.linkedin.com/posts/c-ray-therpeutics_xdc-2026-recap-activity-7445077543470403584-SM1L?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY 🎤 Several days ago, we took a step — bringing together leading voices from across the global RDC ecosystem at XDC 2026. Isotope producers, ligand innovators, clinical-stage developers. Not just to share a stage, but to see Chengdu. Because Chengdu is not just a conference venue. It has become one of China's most significant radiopharmaceutical hubs — in infrastructure, in policy support, in the speed at which things get built. Visiting the Chengdu Medical City, our guests saw that firsthand. And what they saw in C-Ray was something specific: a single site where the full chain lives — from process development and radiolabeling to cGMP manufacturing and cold-chain logistics. One site. One stop. The conversations on stage reflected exactly why that matters. Ligand platforms are diversifying. Novel isotopes are moving from supply bottleneck to clinical reality. New therapeutic modalities are expanding what radiopharmaceuticals can treat and how. These are not separate trends — they are converging. And they all require the same thing: a manufacturing and development partner who can move with them. That is the role C-Ray was built to play. We are a radiopharmaceutical CRDMO headquartered in Chengdu — at the intersection of China's growing capabilities and the global pipeline that needs them. This is just the beginning. To every speaker, partner, and delegate who made the journey: thank you! 🌹 NorthStar Medical Radioisotopes, LLCThor Medical ASA, Navigo, Oncoinvent ASA And to those who haven't yet — we hope to welcome you to Chengdu, to this industry's next chapter, and to C-Ray. 👐 #XDC2026 #Radiopharmaceuticals #CRDMO #RDC #Chengdu #AlphaTherapy #NuclearMedicine #ligand #isotope #Ac225 #Pb212 #Lu177
- ·10 t sittenThere should be a minimum requirement for volume on the opening/closing auctions. I think it's a joke.·4 t sittenIt would have been better if there was a rule that everyone HAD to show their portfolio for stocks they comment on so that people can decide how seriously they want to take the comment from that particular person. Ideally, everyone has skin in the game. Why is one here pumping up the stock while one themselves only has 4% invested in the stock? If it is as good as one says, then why not have 20, 30 or 40% of their portfolio in TRMED? Perhaps the number of shares and average cost basis would also have been interesting? Someone who has an average cost basis of 0.8kr is perhaps euphoric and should perhaps not give advice to others who have an average cost basis of 3 or 4kr for example?
- ·10 t sittenThe shorts are bleeding now :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 782 | - | - | ||
| 15 000 | - | - | ||
| 2 217 | - | - | ||
| 2 070 | - | - | ||
| 513 | - | - |
Välittäjätilasto
Dataa ei löytynyt